The genes expressed - turned on, off, up or down - in any given cell determine its type and function. When the wrong genes are expressed at the wrong time or in the wrong amounts, it can lead to disease.
At Syros, we have identified cancer patients with aberrant expression of genes that can be targeted with new therapies. We are focused on applying this approach to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded current targeted approaches, we are advancing our late-stage clinical pipeline to provide new treatment options. We invite you to learn more about Syros and our mission to improve the lives of cancer patients.
By controlling gene expression with our small molecule therapies, we aim to make a profound difference in the lives of patients and their families. We are currently developing tamibarotene for genomically defined subsets of MDS and AML patients.
A selective oral RARα agonist in clinical development for genomically defined subsets of patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia.
A novel oral form of arsenic trioxide previously in clinical development for patients with acute promyelocytic leukemia.
A highly selective and potent oral CDK7 inhibitor previously in clinical development for pancreatic cancer.
Regulatory regions of the genome control the expression of genes, turning them on, off, up or down, like dimmer switches and determining how a cell behaves. Because gene expression is fundamental to the function of all cells, alterations in these regulatory regions contribute to virtually all diseases. Until recently, however, scientists lacked the tools to study these regulatory regions, rendering them largely unexploited for drug discovery and development.
Our gene control platform has led us to discover several targets for small molecule drugs, with the aim to address certain cancers that have eluded other genomics-based approaches.
Learn more about the types of cancers we aim to treat.
A team with a proven record of translating innovative science into important therapies.
We're sorry, but your request could not be completed at this time. Error: Authenication Error
Collaborative to our core and driven to make a difference for patients, we take on big challenges in our shared pursuit of big breakthroughs.
Transforming lives through novel gene control medicines.
Syros to Participate in Upcoming Investor Conferences
Piper Sandler 35th Annual Healthcare Conference
USE OF TAMIBAROTENE, A POTENT AND SELECTIVE RARΑ AGONIST, IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH RELAPSED AND REFRACTORY AML WITH RARA GENE OVEREXPRESSION